Journey Medical (DERM) Gains from Investment Securities (2020 - 2026)

Journey Medical has reported Gains from Investment Securities for 7 years, with the latest figure at $10000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 99.59% year-over-year to $10000.0; the trailing twelve-month figure through Mar 2026 stood at $10000.0 (down 99.59% YoY), and the FY2025 full-year result was $1.5 million, down 38.93% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $10000.0, down from $1.5 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $3.1 million in Q2 2023, with the low at $7000.0 in Q1 2023.
• Historically, Gains from Investment Securities has averaged $1.2 million across 5 years, with a median of $887500.0 in 2024.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities surged 14800.0% — and 2026, when it tumbled 99.59%.
• Journey Medical's Gains from Investment Securities stood at $149000.0 in 2022, then sank by 35.57% to $96000.0 in 2023, then slumped by 78.12% to $21000.0 in 2024, then surged by 7088.3% to $1.5 million in 2025, then tumbled by 99.34% to $10000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $10000.0 (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.